DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis

Author:

Dragomir Mihaela12ORCID,Călugăru Onda-Tabita2,Popescu Bogdan3,Jardan Cerasela23,Jardan Dumitru4,Popescu Monica2,Aposteanu Silvia2,Bădeliță Sorina2ORCID,Nedelcu Gabriela2,Șerban Cătălin2,Popa Codruța23,Vassu-Dimov Tatiana1,Coriu Daniel23

Affiliation:

1. Faculty of Biology, University of Bucharest, 030018 Bucharest, Romania

2. Fundeni Clinical Institute, 022328 Bucharest, Romania

3. Hematology Department, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania

4. Molecular Biology Laboratory, Medlife Bucharest, 010093 Bucharest, Romania

Abstract

Multiple myeloma is a hematologic neoplasm caused by abnormal proliferation of plasma cells. Sequencing studies suggest that plasma cell disorders are caused by both cytogenetic abnormalities and oncogene mutations. Therefore, it is necessary to detect molecular abnormalities to improve the diagnosis and management of MM. The main purpose of this study is to determine whether NGS, in addition to cytogenetics, can influence risk stratification and management. Additionally, we aim to establish whether mutational analysis of the CD138 cell population is a suitable option for the characterization of MM compared to the bulk population. Following the separation of the plasma cells harvested from 35 patients newly diagnosed with MM, we performed a FISH analysis to detect the most common chromosomal abnormalities. Consecutively, we used NGS to evaluate NRAS, KRAS, BRAF, and TP53 mutations in plasma cell populations and in bone marrow samples. NGS data showed that sequencing CD138 cells provides a more sensitive approach. We identified several variants in BRAF, KRAS, and TP53 that were not previously associated with MM. Considering that the presence of somatic mutations could influence risk stratification and therapeutic approaches of patients with MM, sensitive detection of these mutations at diagnosis is essential for optimal management of MM.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference57 articles.

1. American Cancer Society (2023, August 08). Survival Rates for Multiple Myeloma. Available online: https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/survival-rates.html.

2. Interpretation of Cytogenetic Results in Multiple Myeloma for Clinical Practice;Rajan;Blood Cancer J.,2015

3. Wiedmeier-Nutor, J.E., and Bergsagel, P.L. (2022). Review of Multiple Myeloma Genetics Including Effects on Prognosis, Response to Treatment, and Diagnostic Workup. Life, 12.

4. Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management;Rajkumar;Am. J. Hematol.,2022

5. Mutational Landscape Reflects the Biological Continuum of Plasma Cell Dyscrasias;Rossi;Blood Cancer J.,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3